UTAA09 injection for relapsed or refractory blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an investigational cell therapy called UTAA09 for people with CD19-positive B-cell blood cancers that have come back or not responded to treatment. It aims to see if this treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and 70 years old.
- You have a CD19-positive B-cell blood cancer that has relapsed or is refractory (did not respond to treatment).
- Your doctor expects you to live longer than 12 weeks.
- You are able to do daily activities with little or no help (ECOG score 0-2).
- Your heart, liver, kidneys, and lungs are working well enough based on blood tests and other checks.
- You agree to participate and sign a consent form after understanding the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called UTAA09 for people with certain types of lymphoma that have not been treated with CAR T-cells before. It aims to see if the treatment is safe and works against tumors that have CD19 or CD20 proteins.
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are made from a donor to attack cancer cells in people with B-cell blood cancers that have come back or not responded to standard treatments. The goal is to see if these cells can help people who haven't had success with other therapies.
This trial tests a new cell therapy called UTAA07 for people with blood or lymph cancers that have returned or not responded to other treatments. It is designed for cancers that carry a specific marker called CD7, and aims to see if this therapy can help control the disease.
This trial tests a new injection called UTAA91 for people with hard-to-treat rheumatoid arthritis. It's for those who have tried standard treatments without success.
Hear when a new CD19-positive Relapsed or Refractory B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.